Short‑course bortezomib‑based retreatment for patients with multiple myeloma who had received bortezomib‑thalidomide‑dexamethasone (VTD) as an initial therapy: A single‑center case series
- Authors:
- Published online on: January 23, 2014 https://doi.org/10.3892/etm.2014.1496
- Pages: 977-981
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Studies have shown that the bortezomib‑based retreatment of patients with multiple myeloma (MM) may prolong control of the disease. The optimal duration of bortezomib‑based retreatment in relapsed or refractory MM is unknown. The present retrospective study evaluated the efficacy and safety of short‑course bortezomib‑based retreatment in patients who had received bortezomib‑thalidomide‑dexamethasone (VTD) treatment for the initial therapy of newly diagnosed MM. The clinical records of 20 patients who had received short‑course bortezomib‑based retreatment in a single center were reviewed. Patients received a median of two cycles of bortezomib as the retreatment and the overall response rate was 90%. Six (30%), eight (40%) and four (20%) patients achieved a complete response (CR), a very good partial response and a partial response, respectively. Of the 10 patients who had achieved a CR during the initial VTD treatment, six experienced a repeat CR during the retreatment. The median duration of the response was nine months and the median time to progression was 10.5 months. The most common grade I and II adverse events were thrombocytopenia and neutropenia. The short‑course bortezomib‑based retreatment was well tolerated and the favorable response rates observed suggest that it may be an effective and convenient treatment option for certain patients, particularly elderly patients.
